These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 33675520

  • 21. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, Wang FR, Zhao T, Liu YR, Liu KY, Huang XJ.
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2185-2191. PubMed ID: 26253005
    [Abstract] [Full Text] [Related]

  • 22. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Nishio H, Matsuo M, Imadome K, Iijima K.
    Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
    [Abstract] [Full Text] [Related]

  • 23. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y, Chen J, Wu D.
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [Abstract] [Full Text] [Related]

  • 24. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE, Mocroft A, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Iversen M, Kirkby NS, Rasmussen A, Sørensen SS, Lundgren JD, MATCH in PERSIMUNE study group.
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [Abstract] [Full Text] [Related]

  • 25. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DDH, Lipton JH, Kumar R, Messner H, Viswabandya A.
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [Abstract] [Full Text] [Related]

  • 26. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
    [Abstract] [Full Text] [Related]

  • 27. Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.
    Dutta R, Miao SY, Phan P, Fernandez-Pol S, Shiraz P, Ho D, Mannis GN, Zhang TY.
    J Med Case Rep; 2021 Mar 28; 15(1):170. PubMed ID: 33773605
    [Abstract] [Full Text] [Related]

  • 28. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep 28; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 29. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Sep 28; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 30. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
    Lindsay J, Othman J, Yong MK, Ritchie D, Chee L, Tay K, Tio SY, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SC, Kong DCM, Greenwood M, Pergam SA, Liu C, Slavin MA.
    Transpl Infect Dis; 2021 Oct 28; 23(5):e13719. PubMed ID: 34453768
    [Abstract] [Full Text] [Related]

  • 31. Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.
    Pegoraro F, Favre C.
    Ann Hematol; 2021 Apr 28; 100(4):865-878. PubMed ID: 33547921
    [Abstract] [Full Text] [Related]

  • 32. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, Beneyto I, Espí J, Gómez-Codina J, Iacoboni G, Jarque I, López-Andújar R, Mayordomo-Aranda E, Montalar J, Pastor A, Pastor M, Piñana JL, Rojas-Ferrer N, Sánchez-Lázaro I, Sandoval J, Sanz G, Sanz MÁ, Solé A, Sanz J.
    Leuk Lymphoma; 2019 Jan 28; 60(1):142-150. PubMed ID: 29966464
    [Abstract] [Full Text] [Related]

  • 33. Successful HLA-haploidentical stem cell transplantation with post-transplant cyclophosphamide in an older patient with chronic active Epstein-Barr virus infection.
    Maegaki M, Kawamura K, Hara K, Hosoda R, Suzuki S, Hosoda Y, Imadome KI, Motokura T, Fukuda T.
    Int J Hematol; 2022 Oct 28; 116(4):630-634. PubMed ID: 35438460
    [Abstract] [Full Text] [Related]

  • 34. Epstein-Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis.
    Satou A, Kohno A, Fukuyama R, Elsayed AA, Nakamura S.
    Hum Pathol; 2017 Jan 28; 59():147-151. PubMed ID: 27569297
    [Abstract] [Full Text] [Related]

  • 35. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review.
    Chen S, An L, Han J, Zheng X, Zhang X, Li G, Zhang Y, Cao W, Lv M, Yang D, Jiang E, Pang A, Feng S.
    Transpl Immunol; 2023 Oct 28; 80():101895. PubMed ID: 37414267
    [Abstract] [Full Text] [Related]

  • 36. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation.
    Tsushima T, Masuda SI, Yoda N, Kainuma S, Kimeda C, Konno S, Tanaka K, Matsuo K, Shimoji S, Kimura K, Arai H, Utsu Y, Imadome KI, Aotsuka N.
    Ann Hematol; 2024 Mar 28; 103(3):935-946. PubMed ID: 38157001
    [Abstract] [Full Text] [Related]

  • 37. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
    Chen DB, Liu XY, Kong FZ, Jiang Q, Shen DH.
    J Clin Pathol; 2021 Nov 28; 74(11):697-703. PubMed ID: 34011618
    [Abstract] [Full Text] [Related]

  • 38. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.
    Transplantation; 1999 Oct 15; 68(7):997-1003. PubMed ID: 10532541
    [Abstract] [Full Text] [Related]

  • 39. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A.
    Pediatr Int; 2017 Sep 15; 59(9):973-978. PubMed ID: 28581032
    [Abstract] [Full Text] [Related]

  • 40. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC, Medinger M, Halter JP, Baldomero H, Hirsch HH, Tzankov A, Dirnhofer S, Passweg JR, Tichelli A.
    Hematology; 2014 Jul 15; 19(5):280-5. PubMed ID: 24074746
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.